<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32445195</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.</ArticleTitle><Pagination><StartPage>182</StartPage><EndPage>186</EndPage><MedlinePgn>182-186</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.26989</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 has created unprecedented challenges for amyotrophic lateral sclerosis (ALS) clinical care and research in the United States. Traditional evaluations for making an ALS diagnosis, measuring progression, and planning interventions rely on in-person visits that may now be unsafe or impossible. Evidence- and experience-based treatment options, such as multidisciplinary team care, feeding tubes, wheelchairs, home health, and hospice, have become more difficult to obtain and in some places are unavailable. In addition, the pandemic has impacted ALS clinical trials by impairing the ability to obtain measurements for trial eligibility, to monitor safety and efficacy outcomes, and to dispense study drug, as these also often rely on in-person visits. We review opportunities for overcoming some of these challenges through telemedicine and novel measurements. These can reoptimize ALS care and research in the current setting and during future events that may limit travel and face-to-face interactions.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Jinsy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>The Neurological Institute, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carberry</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Neurological Institute, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dedi</LastName><ForeName>Brixhilda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Neurological Institute, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healey Center for ALS, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8574-5332</Identifier><AffiliationInfo><Affiliation>Neurology, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD020007</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="N">Enteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006699" MajorTopicYN="Y">Home Care Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017051" MajorTopicYN="Y">Hospice Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013147" MajorTopicYN="N">Spirometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="Y">Telemedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012122" MajorTopicYN="N">Ventilators, Mechanical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014910" MajorTopicYN="N">Wheelchairs</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical care</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword></KeywordList><CoiStatement>J.A. has consulted for Avexis, AL&#x2010;S Pharma, Biogen, and Cytokinetics, and has received research grants from Neuraltus, Roche, Biogen, and Novartis. J.B. has consulted for Biogen, Clene Nanomedicine, and Alexion, and has received research support from Alexion, Biogen, MT Pharma of America, Amylyx Therapeutics, Anelixis Therapeutics, Brainstorm Cell Therapeutics, Genentech, nQ Medical, the National Instutes for Health/National Institute of Neurological Disorder and Stroke (NINDS/NIH), the Muscular Dystrophy Association (MDA), and ALS One. R.B. has consulted for Modulus Pharmaceuticals, Mitochondria in Motion, Acurastem, Sarepta, and Kite Pharma, and has received research grants from the NINDS/NIH, California Institute for Regenerative Medicine, Target ALS, Burroughs Wellcome Fund, the MDA, and the Charcot&#x2013;Marie&#x2010;Tooth Association. M.C. has consulted for Biogen, Cytokinetics, Sunovian, AL&#x2010;S Pharma, Avexis, and Takeda. J.G. has research support from the NIH, ALSA, and the MDA, and clinical trial funding from Biogen, Genentech, Amylyx, Cytokinetics, and the Healy Center at Massacusetts General Hospital. N.M. has consulted for Orion, Apellis, Brainstorm Cell Therapeutics, and Clene Nanomedicine, and has received research support from the Department of Defense ALSRP, Answer ALS, the ALS Association, the NIH/NINDS, Biogen, and Clene. T.M.M. has licensing agreements with C2N and Ionis Pharmaceuticals, has served on advisory boards for and receives material support from Biogen and Ionis Pharmaceuticals, and is a consultant for Cytokinetics and Disarm Therapeutics. S.P. reports personal consulting fees for advisory panels from Orion Corp and reports research grant suppport from Amylyx Therapeutics, Revalesio Corporation, Ra Pharma, Biohaven, Clene, Prilenia, the ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, and the Spastic Paraplegia Foundation. J.R. has consulted for Expansion therapeutics and received research grants from the NIH/NINDS, the NIH/National Institute on Aging, the Department of Defense, the Chan Zuckerberg Initiative, the ALS Association, the MDA, Target ALS, F Prime, Travelers Insurance, American Airlines, ALS Finding a Cure, Answer ALS, Team Gleason, and Microsoft. Z.S. has consulted for Amylyx, Biogen, Biohaven, and Cytokinetics, and has received research support from Biogen, Biohaven, and Cytokinetics. M.W. has consulted for Biogen, Ra Pharma, and Argenx; is a speaker for Nufactor; and has received research support from ALSA and ALS Finding a Cure. R.B. has research support from ALSA and Orion, and consulting support from Amylyx, Alexion, ALSA, Biogen, Brainstorm Cell, ITF Pharma, Mallinkrodt, New Biotic, and Woolsey Pharma. N.C., B.D., and J.S. declare no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32445195</ArticleId><ArticleId IdType="pmc">PMC7283687</ArticleId><ArticleId IdType="doi">10.1002/mus.26989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International MG/COVID&#x2010;19 Working Group . Guidance for the management of myasthenia gravis (MG) and Lambert&#x2010;Eaton myasthenic syndrome (LEMS) during the COVID&#x2010;19 pandemic. J Neurol Sci. 2020; 412:116803 10.1016/j.jns.2020.116803 Epub 2020 Mar 25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116803</ArticleId><ArticleId IdType="pmc">PMC7105910</ArticleId><ArticleId IdType="pubmed">32247193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassardjian CD, Desai U, Narayanaswami P. AANEM Quality and Safety Committee of the AANEM. Practical guidance for managing EMG requests and testing during the COVID&#x2010;19 pandemic. Muscle Nerve. 2020; 10.1002/mus.26891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26891</ArticleId><ArticleId IdType="pmc">PMC7262302</ArticleId><ArticleId IdType="pubmed">32277763</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajabally YA, Goedee HS, Attarian S, Hartung HP. Management challenges for chronic dysimmune neuropathies during the COVID&#x2010;19 pandemic. Muscle Nerve. 2020; 10.1002/mus.26896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26896</ArticleId><ArticleId IdType="pmc">PMC7264511</ArticleId><ArticleId IdType="pubmed">32311114</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerapandiyan A, Wagner KR, Apkon S, et al. The care of patients with Duchenne, Becker and other muscular dystrophies in the COVID&#x2010;19 pandemic. Muscle Nerve. 2020; 10.1002/mus.26902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26902</ArticleId><ArticleId IdType="pmc">PMC7264600</ArticleId><ArticleId IdType="pubmed">32329920</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerapandiyan A, Connolly AM, Finkel RS, et al. Spinal muscular atrophy care in the COVID&#x2010;19 pandemic era. Muscle Nerve. 2020; 10.1002/mus.26903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26903</ArticleId><ArticleId IdType="pmc">PMC7264534</ArticleId><ArticleId IdType="pubmed">32329921</ArticleId></ArticleIdList></Reference><Reference><Citation>
Northeastern ALS Consortium
. NEALS member sites.
https://www.neals.org/about-us/neals-member-sites. Accessed May 5, 2020.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497&#x2010;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>
American Academy of Neurology
. Telemedicine and COVID&#x2010;19. https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist&#x2013;administrators/telemedicine-and-remote-care/20200326-telemedicine-and-covid-19-final.pdf. Accessed May 5, 2020.</Citation></Reference><Reference><Citation>Palese F, Sartori A, Logroscino G, Pisa FE. Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:176&#x2010;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">30656971</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E, Bianchi E, Poloni M, Beghi E, SLALOM Group . Is firstly diagnosed ALS really ALS? Results of a population&#x2010;based study with long&#x2010;term follow&#x2010;up. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:221&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">27892707</ArticleId></ArticleIdList></Reference><Reference><Citation>Geronimo A, Wright C, Morris A, Walsh S, Snyder B, Simmons Z. Incorporation of telehealth into a multi&#x2010;disciplinary ALS clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:555&#x2010;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">28678542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Montes J, et al. Excellent inter&#x2010;rater, intra&#x2010;rater, and telephone administered reliability of the ALSFRS&#x2010;R in a multi&#x2010;center trial. Amyotroph Lateral Scler. 2007;8:42&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17364435</ArticleId></ArticleIdList></Reference><Reference><Citation>
American Thoracic Society
. Pulmonary function laboratories: advice regarding COVID&#x2010;19. https://www.thoracic.org/professionals/clinical-resources/disease-related-resources/pulmonary-function-laboratories.php. Accessed May 5, 2020.</Citation></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol. 2018;75:58&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833488</ArticleId><ArticleId IdType="pubmed">29181534</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarkis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence&#x2010;based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218&#x2010;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry. 2015;86:496&#x2010;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">25550416</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui F, Sun L, Xiong J, Li J, Zhao Y, Huang X. Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta&#x2010;analysis. PLoS One. 2018;13:e0192243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800689</ArticleId><ArticleId IdType="pubmed">29408898</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulley MT, Brittain R, Hodges W, et al. Multidisciplinary amyotrophic lateral sclerosis telemedicine care: the store and forward method. Muscle Nerve. 2019;59:34&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">29802746</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkirk SM, Washington MO, McClellan F, Flynn B, Seton JM, Strozewski R. Delivering tertiary centre specialty care to ALS patients via telemedicine: a retrospective cohort analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:324&#x2010;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427284</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Rijn M, Paganoni S, Levine&#x2010;Weinberg M, et al. Experience with telemedicine in a multi&#x2010;disciplinary ALS clinic. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:143&#x2010;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">29250986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong M, Gutierrez M, Marcin J. Interstate licensure for telemedicine: the time has come. Virtual Mentor. 2014;16:1010&#x2010;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">25493371</ArticleId></ArticleIdList></Reference><Reference><Citation>
Center for Medicare Services
. https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet. Accessed May 11, 2020.</Citation></Reference><Reference><Citation>Bloom B, Dorsey E, Okun M. The coronavirus disease 2019 crisis as a catalyst for telemedicine for chronic neurological disorders. JAMA Neurol. 2020; 10.1001/jamaneurol.2020.1452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1452</ArticleId><ArticleId IdType="pubmed">32329796</ArticleId></ArticleIdList></Reference><Reference><Citation>
Federation of State Medical Boards
. https://www.fsmb.org/siteassets/advocacy/pdf/states-waiving-licensure-requirements-for-telehealth-in-response-to-covid-19.pdf. Accessed May 11, 2020.</Citation></Reference><Reference><Citation>
Ryan C. Computer and Internet Use in the United States: 2016. American Community Survey Reports. US Census Bureau. ACS&#x2010;39. August 2018. https://www.census.gov/content/dam/Census/library/publications/2018/acs/ACS-39.pdf
</Citation></Reference><Reference><Citation>Van den Berg L, Kalmihn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patient with ALS. Neurology. 2005;65:1264&#x2010;1267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247055</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996&#x2010;2000. J Neurol Neurosurg Psychiatry. 2003;74:1258&#x2010;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738639</ArticleId><ArticleId IdType="pubmed">12933930</ArticleId></ArticleIdList></Reference><Reference><Citation>Haulman A, Geronimo A, Chahwala A, Simmons Z. The use of telehealth to enhance care in ALS and other neuromuscular disorders. Muscle Nerve. (to be published). 2020;61:682&#x2010;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">32297678</ArticleId></ArticleIdList></Reference><Reference><Citation>Geronimo A, Simmons Z. Evaluation of remote pulmonary function testing in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:348&#x2010;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">30957547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S, O&#x2010;Connell C, Kass L, Graff G. Single&#x2010;breath counting: a pilot technique for measuring pulmonary functions in children. Am J Emerg Med. 2011;29:33&#x2010;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">20825771</ArticleId></ArticleIdList></Reference><Reference><Citation>
US Food and Drug Administration
. Use of electronic informed consent: questions and answers, guidance for institutional review boards, investigators and sponsors. December 2016. https://www.fda.gov/media/116850/download. Accessed May 5, 2020.</Citation></Reference><Reference><Citation>Panda N, Solsky I, Huang EJ, et al. Using smartphones to capture novel recovery metrics after cancer surgery. JAMA Surg. 2019;155:1&#x2010;7. 10.1001/jamasurg.2019.4702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2019.4702</ArticleId><ArticleId IdType="pmc">PMC6820047</ArticleId><ArticleId IdType="pubmed">31657854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cote DJ, Barnett I, Onnela JP, Smith TR. Digital phenotyping in patients with spine sisease: A novel approach to quantifying mobility and quality of life. World Neurosurg. 2019;126:e241&#x2010;e249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706326</ArticleId><ArticleId IdType="pubmed">30797933</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Gancedo L, Kelly ML, Lavrov A, et al. Objectively monitoring amyotrophic lateral sclerosis patient symptoms during clinical trials with sensors: observational study. JMIR Mhealth Uhealth. 2019;7:e13433. 10.2196/13433.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13433</ArticleId><ArticleId IdType="pmc">PMC6942190</ArticleId><ArticleId IdType="pubmed">31859676</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>